Business
Homology Medicines Appoints Albert Seymour, Ph.D., Chief Executive Officer
Arthur Tzianabos, Ph.D., Named Chairperson of the Board of Directors BEDFORD, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq:
About this update from Q32 Bio Inc.
[{"type":"text","content":"Arthur Tzianabos, Ph.D., Named Chairperson of the Board of Directors BEDFORD, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the promotion of Albert Seymour, Ph.D., to Chief Executive Officer (CEO), President and member of the Board of Directors. He is succeeding Arthur Tzianabos, Ph.D., who has been appointed as Chairperson of Homology’s Board of Directors. Dr. Tzianabos and Dr. Seymour joined Homology in 2016 as CEO & President and Chief Scientific Officer, respectively, and they helped to build the Company into a clinical-stage organization with programs spanning nuclease-free gene editing, gene therapy and gene therapy-delivered monoclonal antibodies (GTx-mAb). “We believe Homology has a clear path forward with our clinical programs and is in a strong financial position. We expect that the multiple validating business development deals we have done and our recent pipeline prioritization will allow us to progress through several key milestones. The time is right to make this transition in leadership to Albert, who has been instrumental in expanding and advancing Homology’s pipeline of genetic medicines and with whom I have worked closely for the past six-and-a-half years at Homology and previously during our time at Shire,” stated Dr. Tzianabos. “Albert is a seasoned scientific executive who has also led Clinical Development and Operations, Commercial and Human Resources at the Company. I will work closely with Albert and the team as Homology progresses, while I evaluate opportunities to help create and build innovative biotech companies that can translate new technologies into potential treatments for patients.” “I am honored and excited to lead the talented and committed team of colleagues at Homology as we continue on our mission to deliver genetic medicines to people who need them,” stated Dr. Seymour. “With our solid scientific and operational foundation, we are keenly focused on clinical trial execution and building value for our shareholders. We anticipate providing program updates at the end of this year for HMI-103, our in vivo nuclease-free gene editing candidate for PKU, and HMI-203, our gene therapy candidate for Hunter syndrome. I want to thank Arthur for his leadership of Homology and his past and future support. I look forward to w...